Shots: Esperion to receive $150M upfront, $150M sales milestones and up to $900M regulatory milestones including royalties. Daiichi to get exclusive commercialization rights for Esperion’s bempedoic acid and bempedoic acid […]readmore
Tags : ~1.2B
Shots: Arena to get $1.2B as total deal value, including $800M upfront plus $400M milestones and royalties on net sales of the product. United to get exclusive worldwide rights to […]readmore
Shots: Pacific to get $8.00/share making $1.2B as total deal value in cash, with its expected closure in Q2’19 The acquisition is a focus to combine Pacific’s Sequel SMRT Technology […]readmore